Form 4: Exact Sciences Director Sells Shares Post-Merger

Exact Sciences Director Michael J. Barber reported the disposition of all common stock and deferred stock units following the company's merger with Abbott Laboratories.

Summary

• Michael J. Barber, a Director of Exact Sciences Corporation (EXAS), reported changes in beneficial ownership.
• The transactions occurred on March 23, 2026, coinciding with the merger of Exact Sciences into Badger Merger Sub I, Inc., a wholly-owned subsidiary of Abbott Laboratories.
• Each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash.
• Barber disposed of 7,738 shares and an additional 5,398 shares of common stock, resulting in 0 shares beneficially owned.
• 7,422 Deferred Stock Units (DSUs) held by Barber were also fully vested, cancelled, and converted into the right to receive the $105.00 per share merger consideration.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral event from a reporting perspective, as it simply confirms the execution of a pre-announced merger and the subsequent disposition of shares by an insider, which is a positive for shareholders receiving the cash consideration.

Positives

• The merger provided a cash consideration of $105.00 per share to Exact Sciences shareholders.
• Deferred Stock Units (DSUs) were fully vested and converted into cash, benefiting the holder.

Negatives

• Exact Sciences Corporation ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Abbott Laboratories.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects the finalization of a significant acquisition in the diagnostics and life sciences sector, where a larger player like Abbott Laboratories integrates a specialized company like Exact Sciences. Such mergers often aim to consolidate market share, expand product portfolios, and leverage R&D synergies.

Comparison to Industry Standards

• The $105.00 per share cash consideration for Exact Sciences common stock can be compared to recent acquisition multiples in the diagnostics and medical technology sector. For instance, similar acquisitions in the past have seen valuations ranging from 3x to 7x revenue, depending on growth prospects and profitability.
• For example, Roche's acquisition of Spark Therapeutics in 2019 was valued at approximately $4.8 billion, representing a significant premium, while Siemens Healthineers' acquisition of Varian Medical Systems in 2020 for $16.4 billion also reflected strategic sector consolidation.
• Without specific financial metrics for Exact Sciences at the time of the merger agreement (e.g., revenue, EBITDA), a direct valuation multiple comparison is limited, but the cash offer indicates a definitive valuation for the company's equity.

Stakeholder Impact

• Shareholders: Received $105.00 per share in cash, representing a definitive exit value for their investment.
• Employees: Exact Sciences employees are now part of Abbott Laboratories, potentially leading to integration challenges or opportunities.
• Customers: Exact Sciences' products and services will now be offered under the Abbott Laboratories umbrella, potentially expanding reach or integrating into a broader portfolio.

Key Dates

Keywords

Exact Sciences, EXAS, Abbott Laboratories, Merger, Form 4, Insider Trading, Stock Sale, Deferred Stock Units, Corporate Acquisition, Michael J. Barber